Real-world psoriasis treatment patterns and disease burden in Germany, with a focus on biologics and apremilast: data from a German statutory health insurance database. admin8. November 2025
Epidemiology of generalized pustular psoriasis in Germany: Analyzing factors influencing prevalence estimates from claims data. admin8. November 2025
Real-World Cost Difference in Patients With Psoriasis Initiating Apremilast vs. Secukinumab After Conventional Systemic Therapy Using German Sickness Fund Data. admin8. November 2025
Real-World Cost Difference in Patients with Psoriasis Newly Initiating Apremilast vs. Biologic Treatment after Conventional Systemic Therapy: A Retrospective Analysis of German Sickness Fund Data. admin8. November 2025
PSY17 REAL-WORLD COST DIFFERENCE IN PATIENTS WITH PSORIASIS NEWLY INITIATING APREMILAST VS. BIOLOGIC TREATMENT AFTER CONVENTIONAL SYSTEMIC THERAPY: A RETROSPECTIVE ANALYSIS OF GERMAN SICKNESS FUND DATA. admin8. November 2025
